

6. Scarlatti G, Tresoldi E, Bjorndal A, *et al.*: *In vivo* evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. *Nat Med* 1997;3:1259–1265.
7. Connor RI, Sheridan KE, Ceradini D, *et al.*: Change in co-receptor use correlates with disease progression in HIV-1-infected individuals. *J Exp Med* 1997;185:621–628.
8. De Rossi A, Masiero S, Giaquinto C, *et al.*: Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. *J Clin Invest* 1996;97:323–330.
9. Hunt P, Harrigan P, Huang W, *et al.*: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. *J Infect Dis* 2006;194:926–930.
10. Tersmette M, Gruters R, de Wolf F, *et al.*: Evidence for a role of virulent HIV variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. *J Virol* 1989;63:2118–2125.
11. Tersmette M, de Goede RE, Al BJ, *et al.*: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. *J Virol* 1988;62:2026–2032.
12. Schuitemaker H, Koot M, Kootstra NA, *et al.*: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of diseases is associated with a shift from monocytotropic to T-cell tropic virus population. *J Virol* 1992;66:1354–1360.
13. Koot M, Keet IP, Vos AH, *et al.*: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. *Ann Intern Med* 1993;118:681–688.
14. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. *J Infect Dis* 1994;169:968–974.
15. Ping LH, Nelson JA, Hoffman IF, *et al.*: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Under representation of X4 variants. *J Virol* 1999;73:6271–6281.
16. Gupta P, Urbach A, Cosentino L, *et al.*: HIV-1 isolates from children with or without AIDS have similar *in vitro* biologic properties. *AIDS* 1993;7:1561–1564.
17. Hutto C, Zhou Y, He J, *et al.*: Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease course. *J Virol* 1996;70:3589–3598.
18. Fitzgibbon JE, Gaur S, Gavai M, *et al.*: Effect of the HIV-1 syncytium-inducing phenotype on disease stage in vertically-infected children. *J Med Virol* 1998;55:56–63.
19. McCarthy M, He J, Auger D, *et al.*: Cellular tropisms and co-receptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression. *J Med Virol* 2002;5:67:1–8.
20. Tovo PA, de Martino M, Gabiano C, *et al.*: Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. *Lancet* 1992;339:1249–1253.
21. Bobat R, Coovadia H, Moodley D, *et al.*: Mortality in a cohort of children born to HIV-1 infected women from Durban, South Africa. *South African Med J* 1999;89:646–648.
22. Brumme Z, Goodrich J, Mayer H, *et al.*: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naïve individuals. *J Infect Dis* 2005;192:466–474.
23. Moyle G, Wildfire A, Mandalia S, *et al.*: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. *J Infect Dis* 2005;191:866–872.
24. Isaac C, Tonie C, Polly W, *et al.*: Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. *AIDS Res Hum Retroviruses* 2006;22:458–465.
25. Poveda E, Briz V, de Mendoza C, *et al.*: Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. *J Med Virol* 2007;79:1040–1046.
26. Elizabeth RJ, Lynn SZ, Solomon M, *et al.*: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. *J Virol* 2003;77:7682–7688.
27. Peter WH, Richard PH, Wei H, *et al.*: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. *J Infect Dis* 2006;194:926–930.
28. Tom M, Michael D, Ralph D, *et al.*: HIV-1 co receptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. *J Infect Dis* 2006;194:238–246.
29. Timothy JW, Zhaohui S, Daniel RK, *et al.*: HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. *Clin Infect Dis* 2007;44:591–595.
30. Pierre D, Karine S, Michelle C, *et al.*: R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2005;38:382–392.
31. Ndembu N, Yumo H, Takehisa J, *et al.*: HIV type 1 infection in pygmy-hunter gatherers is from contact with Bantu rather than from non human primates. *AIDS Res Hum Retroviruses* 2003;19:441–445.
32. Xiao L, Owen SM, Goldman I, *et al.*: CCR5 co-receptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR5 usage. *Virology* 1998;240:83–92.
33. Hung CS, Vander HN, Ratner L, *et al.*: Analysis of the critical domain of V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. *J Virol* 1999;73:8216–8226.
34. DeJong JJ, De Ronde A, Keulen W, *et al.*: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino-acid substitution. *J Virol* 1992;66:6777–6780.
35. Fouchier RA, Groenink M, Kootstra NA, *et al.*: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. *J Virol* 1992;66:3183–3187.
36. Briggs DR, Tuttle DL, Sleasman JW, *et al.*: Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophage). *AIDS* 2000;14:2937–2939.
37. Luzuriaga K, Koup RA, Pikora CA, *et al.*: Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. *J Pediatr* 1991;119:230–236.
38. Ljunggren K, Moschese V, Broliden PA, *et al.*: Antibodies mediating cellular cytotoxicity and neutralization correlate

- with a better clinical stage in children born to human immunodeficiency virus-infected mothers. *J Infect Dis* 1990; 161:198–202.
39. Ho S, Shek L, Li A, *et al.*: Co-receptor switch in a macaque infected with CCR5 (R5)-tropic simian-human immunodeficiency virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25–28, 2007 [abstract 71LB].
40. Albert J, Stalhandske P, Marquina S, *et al.*: Biological phenotype of HIV type 2 isolates correlates with V3 genotype. *AIDS Res Hum Retroviruses* 1996;12:821–828.
41. Michael NL, Chang G, Ehrenberg PK, Vahey MT, *et al.*: HIV-1 proviral genotypes from the peripheral blood mono-

nuclear cells of an infected patient are differentially represented in expressed sequences. *J Acquir Immune Def Syndr* 1993;6:1073–1085.

Address reprints request to:

*Hiroshi Ichimura
Department of Viral Infection and International Health
Graduate School of Medical Science
Kanazawa University
13-1 Takara-machi
Kanazawa 920-8640, Japan*

E-mail: ichimura@med.kanazawa-u.ac.jp

